Analysts Set Hologic, Inc. (NASDAQ:HOLX) Price Target at $84.62

Hologic, Inc. (NASDAQ:HOLX) has been assigned an average rating of “Hold” from the seventeen ratings firms that are currently covering the firm, Marketbeat reports. Eleven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $84.62.

Several research firms have issued reports on HOLX. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and cut their target price for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Stephens reiterated an “overweight” rating and issued a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Royal Bank of Canada cut their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Morgan Stanley cut their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Finally, Wolfe Research initiated coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating on the stock.

Hologic Stock Performance

Shares of Hologic stock opened at $64.54 on Friday. The firm has a market cap of $14.48 billion, a P/E ratio of 20.36, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic has a 12 month low of $61.70 and a 12 month high of $84.67. The stock’s fifty day moving average price is $68.19 and its 200-day moving average price is $75.27.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities research analysts expect that Hologic will post 4.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hologic

Institutional investors and hedge funds have recently modified their holdings of the company. General Partner Inc. acquired a new stake in shares of Hologic during the fourth quarter worth about $26,000. Groupama Asset Managment lifted its holdings in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC lifted its holdings in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares during the period. First Horizon Advisors Inc. lifted its holdings in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 260 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.